Quotient Sciences Makes Multi-Million Dollar Investment to Expand Drug Substance Manufacturing Facility

Quotient Sciences is investing £6.3 million ($8.68 million) into their drug substance manufacturing capabilities.

Quotient Sciences, a drug development and manufacturing services provider, announced a £6.3-million ($8.68 million)) investment in its recently acquired manufacturing facility in Alnwick, UK, on Aug. 25, 2021. This investment will expand Quotient’s drug substance manufacturing capability and create 80 jobs over the course of three years.

The Alnwick facility was acquired from Arcinova in February 2021 to expand Quotient’s service portfolio to include drug substance, drug product, and clinical testing capabilities. Their goal is to provide an “end to end” offering from candidate selection through commercial product launch, according to a company press release.

The investment will repurpose a 1500-m² footprint to include additional digital control and data capture equipment. Processing equipment with modular continuous technology designed to maximize responsiveness and agility will also be added. According to the press release, these updates, combined with a five-fold increase in scale, will increase Quotient’s complex medicine development capacity more than tenfold.

“Following our integration into Quotient Sciences earlier in the year, it is tremendously exciting to see the Alnwick facility continue to expand capabilities as we move into larger scale and commercial manufacturing,” said Roger Kilburn, senior vice-president of Candidate Development Services at Quotient Sciences, in the press release. “Science and agility are at the core of Quotient Sciences, and our team strives to innovate and develop smarter approaches to process R&D for our customers and drive the adoption of continuous processing technologies.”

Source: Quotient Sciences